Lexicon Pharmaceuticals announced that Jeff Wade, president and chief operating officer, COO, has decided to step down to pursue new opportunities outside of Lexicon, effective September 30, 2024. A search for a new chief financial officer is ongoing.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on LXRX:
- Lexicon Pharmaceuticals Announces Departure of President and Chief Operating Officer
- Lexicon Pharmaceuticals Announces Executive Leadership Changes
- Lexicon management to meet with Piper Sandler
- Lexicon announces data from STOA-INS CGM Phase 3 trial
- New Secondary Analysis of Phase 3 Data Demonstrates Sotagliflozin Improves Time-In-Range (TIR) and Several Parameters of Glucose Control and Variability in Basal Insulin-Treated Type 2 Diabetes